Catalyst

Slingshot members are tracking this event:

Exelixis' cabozantinib NDA for advanced kidney cancer gets Priority Review, action date (PDUFA) set for June 22

Source Link:
http://seekingalpha.com/news/3061616-exelixis-cabozantinib-nda-advanced-kidney-cancer-gets-priority-review-pdufa-date-june-22

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EXEL
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Cabozantinib is currently marketed as COMETRIQ in the US. 
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 25, 2016
Occurred Source:
http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2161051
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabozantinib, Renal Cell Carcinoma, Priority Review
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.